• First healthy volunteer cohort cleared in Phase 1 first-in-human study of BION-1301 for the treat­ment of IgA nephropathy (IgAN); initial data in healthy volunteers ex­pec­ted in H1 2020 and IgAN patients in H2 2020
• Results from the dose escalation portion of the Phase 1/2 study in re­lapsed or refractory multiple myeloma (MM) patients whose disease progressed after at least three prior ther­a­pies indicated BION-1301 was well tolerated across a wide dose range and no dose limiting toxicities (DLTs) were observed
• 95% target engagement achieved and main­tained; no objective responses observed in the MM patient setting
• Phase 1 dose escalation data in MM to be presented at the 2019 ASCO Annual Meeting

Berkely, CA (Press Release) – Aduro Biotech, Inc. (NASDAQ: ADRO), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on devel­op­ing ther­a­pies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) path­ways for the treat­ment of cancer, auto­immune and inflammatory diseases, today provided an update on its clin­i­cal devel­op­ment pro­grams for BION-1301, a first-in-class humanized IgG4 mono­clonal anti­body that fully blocks APRIL binding to both the BCMA and TACI re­cep­tors.

“We believe the …

Berkeley, CA (Press Release) – Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the United States Patent and Trademark Office has issued a new composition of matter patent related to altered APRIL-binding anti­bodies, further enhancing the com­pany’s B-select intellectual property port­folio. Specifically, the granted claims cover BION-1301, Aduro’s first-in-class anti-APRIL anti­body being eval­u­ated in a Phase 1/2 dose escalation trial for the treat­ment of multiple myeloma.

“Blocking APRIL rep­re­sents a unique ap­proach to treating patients with multiple myeloma and we believe BION-1301 has poten­tial to treat a myriad of on­col­ogy indi­ca­tions as …